McKesson Corporation

Equities

MCK

US58155Q1031

Pharmaceuticals

Real-time Estimate Cboe BZX 02:06:32 2024-03-28 pm EDT 5-day change 1st Jan Change
537.2 USD -0.39% Intraday chart for McKesson Corporation +0.55% +16.01%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Rite Aid reaches bankruptcy settlement with lenders, DOJ, McKesson RE
Mckesson Insider Sold Shares Worth $1,821,762, According to a Recent SEC Filing MT
What has UnitedHealth restored and what is next after major hack? RE
Transcript : McKesson Corporation Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:00 AM
Rockwell Automation Hires New Chief Information Security Officer MT
Deutsche Bank Raises McKesson Price Target to $547 From $517, Maintains Buy Rating MT
UBS Adjusts McKesson Price Target to $620 From $575, Maintains Buy Rating MT
Leerink Partners Starts Coverage on McKesson With Outperform Rating, $600 Price Target MT
The latest transactions by star fund managers Our Logo
US FTC, DHHS Request Information on Shortages of Generic Drugs; McKesson Shares Ease MT
UBS Adjusts McKesson Price Target to $575 From $559, Maintains Buy Rating MT
Mizuho Adjusts Price Target on McKesson to $505 From $450, Keeps Neutral Rating MT
Citigroup Ups Price Target on McKesson to $575 From $530, Maintains Buy Rating MT
Global markets live: Kering, Publicis, Paypal, Mattel, Nvidia... Our Logo
Evercore ISI Adjusts Price Target on McKesson to $560 From $515, Maintains Outperform Rating MT
Baird Raises Price Target on McKesson to $567 From $519, Maintains Outperform Rating MT
McKesson raises annual profit forecast on strong demand for specialty medicines RE
McKesson Fiscal Q3 Adjusted EPS, Revenue Increase; Ups Adjusted EPS Outlook MT
Mckesson Corporation Provides Operating Profit Guidance for the Year 2024 CI
Transcript : McKesson Corporation, Q3 2024 Earnings Call, Feb 07, 2024
McKesson Guides For FY 2024 EPS of $27.25-$27.65, vs Prior View of $26.80-$27.40 and CIQ Analyst Consensus of $27.34/Share MT
McKesson Reports Q3 EPS of $7.74 on Revenue of $80.9 Billion, vs CIQ Analyst Consensus of $7.05/Share on Revenue of $77.8 Billion MT
Tranche Update on McKesson Corporation's Equity Buyback Plan announced on May 24, 2018. CI
McKesson Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Global markets live: Amgen, Chipotle, Ford, Gilead, VF Corp... Our Logo
Chart McKesson Corporation
More charts
McKesson Corporation specializes in pharmaceutical product distribution. The group also offers technological services to healthcare companies. Net sales break down by activity as follows: - distribution of pharmaceutical products (87%); - distribution of medical and surgical products (4%); - other (1.6%): primarily technology services and software sales. The remaining net sales (7.4%) are from international activities.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
19
Last Close Price
539.3 USD
Average target price
547.4 USD
Spread / Average Target
+1.51%
Consensus
  1. Stock
  2. Equities
  3. Stock McKesson Corporation - Nyse
  4. News McKesson Corporation
  5. UBS Adjusts McKesson Price Target to $450 From $440, Maintains Buy Rating